Triple

T19040269
Position Surface form Disambiguated ID Type / Status
Subject GPA E465980 entity
Predicate treatedWith P2367 FINISHED
Object mycophenolate mofetil — NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: mycophenolate mofetil | Statement: [GPA, treatedWith, mycophenolate mofetil]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: mycophenolate mofetil
Context triple: [GPA, treatedWith, mycophenolate mofetil]
  • A. cyclosporine A
    Cyclosporine A is an immunosuppressant drug widely used to prevent organ transplant rejection and treat certain autoimmune diseases.
  • B. Rituxan
    Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
  • C. methotrexate
    Methotrexate is a disease-modifying antirheumatic drug (DMARD) commonly used to treat autoimmune conditions such as rheumatoid arthritis, psoriasis, and certain cancers by inhibiting folate-dependent cell proliferation.
  • D. sulfasalazine
    Sulfasalazine is an anti-inflammatory drug commonly used to treat rheumatoid arthritis and inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.
  • E. indoximod
    Indoximod is an investigational small-molecule immunotherapy drug that modulates the IDO pathway to enhance anti-tumor immune responses in cancer treatment.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: mycophenolate mofetil
Target entity description: Mycophenolate mofetil is an immunosuppressive medication commonly used to prevent organ transplant rejection and to treat various autoimmune diseases.
  • A. cyclosporine A
    Cyclosporine A is an immunosuppressant drug widely used to prevent organ transplant rejection and treat certain autoimmune diseases.
  • B. Rituxan
    Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
  • C. methotrexate
    Methotrexate is a disease-modifying antirheumatic drug (DMARD) commonly used to treat autoimmune conditions such as rheumatoid arthritis, psoriasis, and certain cancers by inhibiting folate-dependent cell proliferation.
  • D. sulfasalazine
    Sulfasalazine is an anti-inflammatory drug commonly used to treat rheumatoid arthritis and inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.
  • E. indoximod
    Indoximod is an investigational small-molecule immunotherapy drug that modulates the IDO pathway to enhance anti-tumor immune responses in cancer treatment.
  • F. None of above. chosen

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d8dd0359648190bc2a9202c5cf29d2 completed April 10, 2026, 11:20 a.m.
NER Named-entity recognition batch_69e5d80054c88190a9d3a49aed504235 completed April 20, 2026, 7:38 a.m.
Created at: April 10, 2026, 12:02 p.m.